Search

everythinglearnresearchcommunity

for

Search:↓

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

A 46-year-old man is using minoxidil, finasteride, and derma rolling for hair regrowth but is unsure of the results and considering a hair transplant. Many suggest he looks good bald and recommend continuing treatment or trying scalp micropigmentation.

The user has been using topical finasteride and minoxidil since February, along with microneedling, and recently noticed increased hair shedding. They are curious if others experienced worsening hair appearance after shedding or if it remained unchanged.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

The conversation is about experiencing hyper-trichosis from taking oral Castor Oil. The user reports increased hair growth on the stomach and legs but is not concerned as it is harmless and will stop when the treatment stops.

The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The user is experiencing noticeable hair improvement after 4.5 months of using a treatment regimen including minoxidil, finasteride, biotin, Nioxin shampoo, microneedling, topical NANoxidil, and copper peptides. Feedback from others is positive, encouraging the user to continue the treatment for at least a year or more.

A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.

A 30-year-old is using topical minoxidil 6% and finasteride for hair loss, showing significant progress over five months. They also use dermastamping, nizoral shampoo, and had a hair and scalp treatment.

The user used topical finasteride 0.3% and minoxidil 6% nightly for 6 months, then added oral finasteride 1mg daily a month ago, which improved hair density. They also started using Flakes shampoo for scalp irritation, finding it more effective than keto shampoo.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

Oral minoxidil can cause skin issues like redness and bumps. The user saw no hair improvement with oral minoxidil but noticed increased facial hair.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

Microneedling promotes hair growth by increasing circulation and collagen production, with gains potentially lasting longer than those from minoxidil. Some users report sustained results after stopping microneedling, unlike with minoxidil and finasteride.

The post discusses a user's 6-month progress using topical finasteride (0.08%) and minoxidil (5%) once a day, combined with scalp micropigmentation (SMP). The user hopes for improved hair growth as they let their hair grow out.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

Minoxidil can cause dark, puffy undereyes. Users suggest using caffeine serum, retinol moisturizer, and Remescar eye bags cream to counteract this effect.

Microneedling once a week at 1mm caused bumps, possibly scars, in the treated area. The user is considering cleaning the skin before microneedling to prevent this issue.

A user who got a hair transplant and gave their experience with it, including how the donor area recovered quickly and the potential risks of getting a hair transplant at a young age. Other users discussed bleaching and dyeing transplanted hair, as well as asking about the clinic where the procedure was done.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The user shared their 6-month hair loss progress using topical minoxidil, oral minoxidil, finasteride, and microneedling. They noted thicker eyebrows and eyelashes but also increased body hair.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user is experiencing severe hair loss and color change despite low testosterone levels and healthy lifestyle changes. They have tried ketoconazole shampoo and consulted a dermatologist, who found no scalp issues but suggested using Toppik for coverage.